<DOC>
	<DOC>NCT00191568</DOC>
	<brief_summary>A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer.</brief_summary>
	<brief_title>Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Pathologically confirmed adenocarcinoma of the pancreas Patient have undergone a potentially curative resection No previous irradiation to the planned field Negative pregnancy test for child bearing women Nonadenocarcinoma pancreatic cancer Treatment with any drug within the last 30 days that has not received regulatory approval. Serious systemic disorder Metastatic disease Pregnancy, breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>